Clinical Trials
Light Chain Bioscience Successfully Completes Factor VIII Mimetic Bispecific Antibody Discovery
Light Chain Bioscience has achieved a milestone and received a payment under its research and collaboration agreement with Takeda Pharmaceutical. The milestone was achieved upon the successful completion of the discovery phase and designation by Takeda of undisclosed bispecific...
Clinical Trials
Chiesi Group Announces Establishment of New Global Rare Diseases Division
Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced the formation of Chiesi Global Rare Diseases, a new business unit that will harness the full resources of the Chiesi Group to advance research and new product development...
Clinical Trials
Iddi intensifies global debate on the future of randomized trials in Clinical Research
International Drug Development Institute (IDDI), a leading therapy-focused Biostatistics and eClinical Services corporation based in Belgium with offices in Boston (MA) and Raleigh (NC) announces that it is hosting a symposium to drive the debate: Are Randomized Clinical Trials...
Clinical Trials
AIVITA Biomedical completes patient enrollment target in phase 2 GBM trial for glioblastoma
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that it has reached its patient enrollment target in the company's phase 2 clinical trial for glioblastoma. The trial has achieved its enrollment target ahead of...
Clinical Trials
Sanofis phase 2 study of BTK inhibitor, SAR442168 meets primary endpoint to treat MS
The Sanofi phase 2b study evaluating its investigational BTK (Brutons tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieved its primary endpoint.
In the trial, SAR442168 significantly reduced disease activity associated with multiple sclerosis (MS) as measured by...
Clinical Trials
Teva Announces Positive Top-Line Results from AJOVY Clinical Trials in Japan
Teva Pharmaceutical Industries Ltd announced positive results from two Phase 2/3 trials evaluating AJOVY® (fremanezumab) in patients in Japan. AJOVY is under development in Japan by Otsuka Pharmaceutical Co., Ltd. (Otsuka) as part of a May 2017 exclusive license...
Clinical Trials
NeuroSense initiates clinical studies to evaluate benefit of PrimeC for ALS patients
NeuroSense Therapeutics, a biotech company developing PrimeC, a combination drug which aims to slow or halt ALS progression, announced the initiation of two clinical studies to evaluate the benefit of PrimeC for ALS patients.
A phase IIa study is being...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read